Aft Pharmaceuticals Ltd. · NZX:AFT
Aft Pharmaceuticals — H1 FY2020 Earnings Presentation
15 slides from Aft Pharmaceuticals's earnings presentation, November 2019
Slide 1: Working to improve your health
Working to improve your health INVESTOR PRESENTATION NOVEMBER 2019
Slide 2: Important Notice
Important Notice This presentation has been prepared by AFT Pharmaceuticals Limited (“AFT”), to provide a general overview of AFT. It is not prepared for any other purpose and must not be provided to any person other than the intended recipient. All amounts are disclosed in New Zealand dollars (NZ$)
Slide 3: H1 FY 2020 Highlights
H1 FY 2020 Highlights 44 countries Maxigesic registered in 24 countries Maxigesic sold in $46.9m operating revenue for H1 FY2020 INVESTOR PRESENTATION NOVEMBER 2019 $13.7m operating profit for H1 FY2020 $7.3m available cash as at 31 September 2019 – up from 6.9m end of FY2019 3
Slide 4: Revenue Growth
Revenue Growth FY2019 Interim FY2019 Annual FY2020 Interim 25.0 50.0 25.0 20.0 40.0 20.0 15.0 30.0 15.0 $m $m $m 10.0 20.0 10.0 5.0 10.0 5.0 19% 9% 64% 112% - - - INVESTOR PRESENTATION NOVEMBER 2019 Australia New Zealand Rest of World Southeast Asia FY2019 Interim FY2019 Annual FY2020 Interim 8.2% 2
Slide 5: Financial performance - Revenue by region and channel
Financial performance - Revenue by region and channel H1 % of H1 % of H1 % of NZ$000's FY2018 total FY2019 total FY2020 total Australia 20,206 55.3% 21,601 56.2% 25,697 54.7% YoY growth 37.9% 6.9% 19.0% New Zealand 14,113 38.6% 12,566 32.7% 13,691 29.2% YoY growth 4.6% -11.0% 9.0% Rest of World 1,62
Slide 6: Consolidated Income Statement
Consolidated Income Statement NZ$'000's Half Year to 30 September H1 % of H1 % of FY2020 revenue FY2019 revenue Revenue 46,946 38,441 Cost of Sales (25,598) 54.5% (20,292) 52.8% Gross Profit 21,348 45.5% 18,149 47.2% Other Income 336 0.7% 2,034 5.3% Selling and distribution expenses (12,938) 27.6% (
Slide 7: Abbreviated Balance Sheet
Abbreviated Balance Sheet Unaudited Audited Unaudited NZ$'000's 30 Sept '19 31 March '19 30 Sept '18 ASSETS Current Assets Inventories 26,835 25,158 27,815 Trade and other receivables 19,998 19,187 12,993 Cash and cash equivalents 7,308 6,916 7,400 Derivative assets 665 - 481 Total current assets 54
Slide 8: Cashflow
Cashflow H1 H1 NZ$'000's Half Year to 30 September FY2020 FY2019 Net cash from / (used in) operating activities 6,135 (2,183) Net cash used in investing activities (2,770) (2,821) Net cash from / (used in) financing activities (2,778) 5,793 Net increase in cash 587 789 Impact of foreign exchange on
Slide 9: Operating profit progress
Operating profit progress NZ$ million 25 20 15 10 5 INVESTOR PRESENTATION NOVEMBER 2019 - FY09 FY10 (5) FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 (10) (15) 9
Slide 10: Development Progress
Development Progress Maxigesic Tablets registered across all of EU o First Maxigesic IV registrations successfully completed in 2019 [AU & NZ] o Maxigesic Oral Liquid filings completed in first countries - 23 countries Maxigesic Hot Drink Sachets regulatory filings to commence December 2019 Maxigesi
Slide 11: Maxigesic Global Update
MAXIGESIC GLOBAL UPDATE [primarily oral dose forms] L i c e n s e d in R u ssi a Ireland – la u n c h e d S i n g a p o re & B r u n e i – l a u n ch e d i n cl u d in g O T C U n i te d K i n g d o m – la u n c h e d C h i n a - l i ce n si n g n e g o t i a t i o n s u n d e r w a y Li ce n si n g
Slide 12: Maxigesic Countries sold and ordered
Maxigesic Countries sold and ordered 120 100 80 60 INVESTOR PRESENTATION NOVEMBER 2019 40 20 0 FY13 FY14 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 12
Slide 13: Maxigesic around the world
Maxigesic around the world Belgium/Luxembourg New Zealand – OTC Australia – OTC Italy – RX – RX Launched Oct 09 Launched Feb 14 Launched April 15 Launching early 2020 CACM- OTC UAE – OTC Ireland – OTC Singapore/Malaysia Launching July 18 Launched Jan 15 Launched July 18 OTC launched June 18 Also sol
Slide 14: Maxigesic going forward
Maxigesic going forward Product Maxigesic Tablets Maxigesic IV Maxigesic oral solution Territories 2020 2019 2020 2019 2020 2019 Licensed 125+ 125+ -% 70 68 3% 122 122 -% Registered 44 42 5% 2 - +++% - - -% Sold in 24 20 20% - - -% - - -% INVESTOR PRESENTATION NOVEMBER 2019 14
Slide 15: Medium Term Plans
Medium Term Plans Further drive International Sales - Keep accelerating countries launched in - Launching new line extensions [Maxigesic IV] Extend International Licensing - Finalise licensing agreement discussions in USA/Canada and LATAM - Finalise licensing agreement discussions in previously unpl
AFT Pharmaceuticals — H1 FY2020 Earnings Presentation on 6ix